Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2003
06/12/2003WO2003048136A1 Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof
06/12/2003WO2003048115A1 Bacterial enzyme inhibitors
06/12/2003WO2003048114A2 Bacterial enzyme inhibitors
06/12/2003WO2003047619A2 Adjuvanted antigenic meningococcal compositions
06/12/2003WO2003047617A2 Vaccine
06/12/2003WO2003047604A1 Use of selenite-containing compounds to be topically or buccally administered
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047564A1 Derivative having hiv integrase inhibitory activity
06/12/2003WO2003047537A1 Antimicrobial composition comprising soy oil, rice bran oil and jojoba oil
06/12/2003WO2003047524A2 Methods and compositions for modulating the immune system and uses thereof
06/12/2003WO2003047516A2 Pyrimidine compounds
06/12/2003WO2003047341A2 Anti-microbial systems and methods
06/12/2003WO2003016273A3 Peptide arginals and methods for treating disseminated intravascular coagulation
06/12/2003WO2001088126A8 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
06/12/2003WO2001071007A3 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
06/12/2003US20030109702 Fungicides, bactericides
06/12/2003US20030109675 Therapy for infections; enzyme inhibitors
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109578 Treating acute and chronical inflammatory processes in a patent in need thereof which comprises administering to such patent an amount effective therefor of a compound or salt thereof according to claim 1.
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109565 Administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol.
06/12/2003US20030109556 Melanocortin receptor ligands
06/12/2003US20030109542 Intermediates and methods of treating a herpesvirus infection, atherosclerosis or restenosis using such compounds or salts.
06/12/2003US20030109538 Pyrmidine derivatives as selective inhibitors of cox-2
06/12/2003US20030109527 Novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy
06/12/2003US20030109525 Provides crystals including a thiazine oxazolidinone. Thiazine oxazolidinones are useful as antimicrobials including gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, gram-negative aerobic
06/12/2003US20030109499 Novel compounds and methods for therapy
06/12/2003US20030109497 Novel imidazolidine derivatives, their preparation and their use
06/12/2003US20030109490 Composite stimulating iNOS enzyme which induce immuno-reactant nitric oxide synthesis and process for preparing the same
06/12/2003US20030109489 Oligosaccharide derivatives and process for producing the same
06/12/2003US20030109477 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
06/12/2003US20030109473 One dose vaccination with mycoplasma hyopneumoniae
06/12/2003US20030109471 Nucleic acid-based compounds and methods of use thereof
06/12/2003US20030109463 Novel macrolides
06/12/2003US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications.
06/12/2003US20030109449 Gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonist of glucogen-like
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109436 Wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. DNA sequence codes for cells
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030109416 methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.
06/12/2003US20030109023 HIV-producing cell line and uses thereof
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108617 Use of a formulation made of or containing at least one dissimilated milk serum
06/12/2003US20030108615 Also comprising a binder, a taste masking layer, a lubricant, and a binder/dissolution enhancer; storage stability; discoloration inhibition; materials handling; easy dosage adjustment
06/12/2003US20030108603 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar
06/12/2003US20030108597 Application of lipid vehicles and use for drug delivery
06/12/2003US20030108588 Reduce restenosis coating on medical device
06/12/2003US20030108572 Antigenic preparations and the isolation of such preparations
06/12/2003US20030108565 Sustained releas of protein using polymer and hydrophobic ion binding; inducing immunology response; autoimmune disease, anticancer agent
06/12/2003US20030108562 Administering gag protein; vaccines for human immunodeficiency virus
06/12/2003US20030108550 Anti-procalcitonin antibodies and the preparation and use thereof
06/12/2003US20030108540 Inducing apoptosis in tissues; binding antibodies
06/12/2003US20030108509 Containing sodium dodecyl sulfate
06/12/2003US20030107149 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
06/12/2003CA2819733A1 Use of selenite-containing compounds to be topically or buccally administered for treating or preventing sunburn
06/12/2003CA2819731A1 Use of selenite-containing compounds to be topically or buccally administered for treating an insect bite
06/12/2003CA2735287A1 Use of selenite-containing compounds to be topically or buccally administered
06/12/2003CA2469671A1 A process for the preparation of a non-toxic anthrax vaccine
06/12/2003CA2468935A1 Adjuvanted antigenic meningococcal compositions
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468907A1 Effectors of innate immunity
06/12/2003CA2468701A1 T-bet compositions and methods of use thereof
06/12/2003CA2468698A1 Methods and compositions for modulating the immune system and uses thereof
06/12/2003CA2468672A1 Antimicrobial composition comprising soy oil, rice bran oil and jojoba oil
06/12/2003CA2468349A1 Pyrimidine compounds
06/12/2003CA2468259A1 Antibody to latent membrane proteins and uses thereof
06/12/2003CA2467486A1 Vaccine
06/12/2003CA2466413A1 Flavivirus ns1 subunit vaccine
06/12/2003CA2463794A1 Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof
06/12/2003CA2414036A1 Zeolitic inhibition of bacilllus anthracis group and its toxins
06/11/2003EP1318407A1 Use of aldose-1-epimerase (mutarotase) for the diagnosis and therapy of infections and sepsis
06/11/2003EP1318406A1 Use of Glycine-N-Acyl-Transferase (GNAT) for diagnosis and therapy of inflammatory diseases and sepsis
06/11/2003EP1318401A2 Method for the early detection of the seroconversion of an anti hepatitis C virus antibody
06/11/2003EP1318149A1 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them
06/11/2003EP1317929A2 Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317923A2 Compositions for increasing the survival of aquatic animals exposed to a RNA virus
06/11/2003EP1317922A1 Antipyretic preparation containing xylitol
06/11/2003EP1317560A1 Self-rearranging dna vectors
06/11/2003EP1317559A2 Dna transfection system for the generation of infectious influenza virus
06/11/2003EP1317555A1 Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses
06/11/2003EP1317537A2 G-csf analog compositions and methods
06/11/2003EP1317536A2 Tnf receptor-like molecules and uses thereof
06/11/2003EP1317488A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine)
06/11/2003EP1317486A1 Interferon-alpha induced gene
06/11/2003EP1317483A2 Variants of allergenic proteins of the group 2 of dermatophagoides
06/11/2003EP1317481A2 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
06/11/2003EP1317474A2 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof
06/11/2003EP1317465A1 Purine derivatives
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317451A1 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317445A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
1 ... 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 ... 1798